FindTrial
Sign In

Safety and Efficacy of Preoperative Weight Loss with GLP-1 Receptor Agonists versus Direct Surgical Treatment for Severe Obesity: A Randomized Controlled Trial (POWER-1)

Safety and Efficacy of Preoperative Weight Loss with GLP-1 Receptor Agonists versus Direct Surgical Treatment for Severe Obesity: A Randomized Controlled Trial (POWER-1)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114393
Enrollment
Unknown
Registered
2025-12-11
Start date
2025-12-15
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Experimental group:Preoperative GLP-1 receptor agonist plus sleeve gastrectomy
Control group:Sleeve gastrectomy

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 18-50 years old; 50 > BMI >= 37.5; no contraindications to GLP-1 receptor agonist application; no contraindications to sleeve gastrectomy; voluntarily join this project and sign informed consent.

Exclusion criteria

Exclusion criteria: History of GLP-1 receptor agonist use within the past six months; history of bariatric surgery; limb disability affecting daily activities; severe cardiopulmonary disease or anatomical abnormalities of the airway that increase anesthesia risk.

Design outcomes

Primary

MeasureTime frame
American Society of Anesthesiologists (ASA) Anesthesia Risk Classification;—

Countries

China

Contacts

Public ContactChen Yi

West China Hospital of Sichuan University

toddy@scu.edu.cn+86 189 8060 6869

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026